BioCardia CardiALLO heart failure trial passes DSMB review; no safety issues

BioCardia, Inc.

DSMB recommends study continue as designed after 30-day safety review of 20M-cell dosing cohort.
No treatment-emergent major adverse cardiac events or immune reactions observed.
Company plans to enroll 39 participants in the US for Phase 1/2 CardiALLO-HF trial.
CEO cites potential for nondilutive funding and partnering, and future pivotal trial in USA, Japan.
High-dose arm targets patients with active inflammation, at least 2x effective dose of prior MSC studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.